Myriad Genetics upgraded to Neutral from Underperform at Credit Suisse Credit Suisse upgraded Myriad Genetics to Neutral based on strong quarterly results and the Crescendo acquisition that adds diversification and accretion. Price target raised to $29 from $18.
Myriad Genetics presents myRisk Hereditary Cancer data at ASCO Myriad Genetics announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting. The myRisk Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Finding deleterious mutations in these genes can help patients with cancer receive appropriate medical care and reduce the risk of second cancers, while patients without cancer can take steps in consultation with their healthcare provider to lower their risk of developing cancer.